Effectiveness of meningococcal serogroup C vaccine programmes

Highlights • Successful glycoconjugate vaccination programmes have reduced the incidence of Meningococcal C (MenC). • Risk of MenC incidence increasing if immunization programmes are not maintained. • Regional differences in vaccination programmes may influence herd protection against MenC. • Adoles...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2013-09, Vol.31 (41), p.4477-4486
Main Authors: Borrow, Ray, Abad, Raquel, Trotter, Caroline, van der Klis, Fiona R.M, Vazquez, Julio A
Format: Article
Language:English
Subjects:
Adolescence
Age
Allergy and Immunology
Antibodies, Bacterial - blood
Applied microbiology
Babies
Bacterial infections
Bacteriology
Biological and medical sciences
Children
Diphtheria
Fundamental and applied biological sciences. Psychology
Humans
Immunization
Immunologic memory
Licenses
Meningitis
Meningitis, Meningococcal - immunology
Meningitis, Meningococcal - microbiology
Meningitis, Meningococcal - prevention & control
Meningococcal serogroup C vaccine
Meningococcal Vaccines - administration & dosage
Meningococcal Vaccines - immunology
Microbiology
Miscellaneous
Monovalent glycoconjugate vaccine
Neisseria meningitidis
Neisseria meningitidis, Serogroup C - immunology
Population
Proteins
Teenagers
Tetanus
Treatment Outcome
Vaccination - methods
Vaccine effectiveness
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Successful glycoconjugate vaccination programmes have reduced the incidence of Meningococcal C (MenC). • Risk of MenC incidence increasing if immunization programmes are not maintained. • Regional differences in vaccination programmes may influence herd protection against MenC. • Adolescence booster vaccinations may be required to maintain herd protection.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2013.07.083